Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.95 |
| ▸ | DHFR | P00374 | 3/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CTSG | P08311 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL29767030 | 1.00 | ADORA2A (0.95) | ADORA2ADHFRPIK3CGPDPK1GDA | |
| SCHEMBL29941435 | 0.98 | ADORA2A (1.00) | ADORA2ADHFRPIK3CGPDPK1GDA | |
| SCHEMBL478917 | 0.98 | ADORA2A (1.00) | ADORA2ADHFRPIK3CGPDPK1GDA | |
| Hydrochloric Acid SCHEMBL6448601 | 0.95 | ADORA2A (0.95) | ADORA2ADHFRPIK3CGPDPK1GDA | |
| SCHEMBL30432637 | 0.81 | ADORA2A (0.70) | ADORA2ADHFRPIK3CGPDPK1GDA | |
| SCHEMBL9014935 | 0.79 | ADORA2A (0.66) | ADORA2ADHFRPIK3CGPIK3CAPIK3CB | |
| SCHEMBL9581658 | 0.76 | ADORA2A (0.63) | ADORA2ADHFRPIK3CGPIK3CAPIK3CB | |
| SCHEMBL13186957 | 0.76 | ADORA2A (0.63) | ADORA2ADHFR | |
| SCHEMBL22055303 | 0.76 | ADORA2A (0.63) | ADORA2ADHFRKDM4EALDH1A1LMNA | |
| SCHEMBL12261736 | 0.76 | ADORA2A (0.63) | ADORA2ADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241429-A1 | Antifolate-Carrying Nanoparticles and Their Use in Medicine | MIDATECH LTD (GB) | 2022-08-04 | — | — | US | disclosed |
| EP-3893938-A1 | ANTIFOLATE-CARRYING NANOPARTICLES AND THEIR USE IN MEDICINE | Midatech Ltd (GB) | 2021-10-20 | — | — | EP | disclosed |
| CN-113423433-A | Nanoparticles carrying antifolates and their use in medicine | MIDA科技有限公司 | 2021-09-21 | — | — | CN | disclosed |
| WO-2020120785-A1 | ANTIFOLATE-CARRYING NANOPARTICLES AND THEIR USE IN MEDICINE | MIDATECH LTD (GB) | 2020-06-18 | — | — | WO | disclosed |
| US-9867828-B2 | Aminopterin dosage forms | AMINOPTERIN LLC (US) | 2018-01-16 | — | — | US | disclosed |
| EP-1855682-B1 | AMINOPTERIN DOSAGE FORMS FOR INFLAMMATORY DISORDERS | AMINOPTERIN LLC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170128452-A1 | Aminopterin Dosage Forms | AMINOPTERIN LLC (US) | 2017-05-11 | — | — | US | disclosed |
| EP-1778237-B1 | Use of Aminopterin for treating acute lymphoblastic leukemia | AMINOPTERIN LLC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20120128703-A1 | Aminopterin Dosage Forms and Methods for Inflammatory Disorders | KAMEN BARTON A (US) | 2012-05-24 | — | — | US | disclosed |
| US-8129383-B2 | Administering tablets containing less than 0.5 mg; uninterrupted dosage cycles; antiinflammatory agent; nontoxic; side effect reduction; antiarthritic agents; psoriasis, multiple, sclerosis, Crohn's disease, Lupus, Graft versus host disease | AMINOPTERIN LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20080096893-A1 | AMINOPTERIN DOSAGE FORMS | SYNTRIX BIOSYSTEMS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-7312217-B2 | Aminopterin dosage forms and methods for inflammatory disorders | SYNTRIX BIOSYSTEMS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1855682-A2 | AMINOPTERIN DOSAGE FORMS AND METHODS FOR INFLAMMATORY DISORDERS | Syntrix Biosystems, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1778237-A1 | USE OF AMINOPTERIN FOR TREATING CANCER AND INFLAMMATORY DISORDERS | Syntrix Biosystems, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006098979-A2 | AMINOPTERIN DOSAGE FORMS AND METHODS FOR INFLAMMATORY DISORDERS | SYNTRIX BIOSYSTEMS, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060205729-A1 | Aminopterin dosage forms and methods for inflammatory disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-14 | — | — | US | disclosed |
| WO-2005089767-A1 | USE OF AMINOPTERIN FOR TREATING CANCER AND INFLAMMATORY DISORDERS | KAMEN BARTON ARON (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050209239-A1 | Compositions and methods employing aminopterin | AMINOPTERIN LLC | 2005-09-22 | — | — | US | disclosed |
| US-4079056-A | REACTING 2,4-DIAMINO-6-PTERIDINE-METHANOL-HBR WITH TRIPHENYLPHOSPHINE DIBROMIDE OR PHOSPHORUS TRIBROMIDE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1978-03-14 | — | — | US | disclosed |
| US-4077957-A | INTERMEDIATE FOR METHOTREXATE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1978-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128452-A1 | Aminopterin Dosage Forms | AADAT, TPMT, ANPEP | SLC6A2 60/4885ADORA2A 212/4885DHFR 795/4885 |
| US-20120128703-A1 | Aminopterin Dosage Forms and Methods for Inflammatory Disorders | AADAT, TPMT, RNPEP | SLC6A2 59/4885ADORA2A 407/4885DHFR 419/4885 |
| US-20060205729-A1 | Aminopterin dosage forms and methods for inflammatory disorders | AADAT, ANPEP, TPMT | SLC6A2 109/4885ADORA2A 275/4885DHFR 793/4885 |
| US-20080096893-A1 | AMINOPTERIN DOSAGE FORMS | AADAT, TPMT, ANPEP | SLC6A2 60/4885ADORA2A 212/4885DHFR 795/4885 |
| US-20220241429-A1 | Antifolate-Carrying Nanoparticles and Their Use in Medicine | FOLR1, FOLR2, SLC19A1 | SLC6A2 1641/4885ADORA2A 1546/4885DHFR 4/4885 |
| US-20050209239-A1 | Compositions and methods employing aminopterin | SLC7A1, AADAT, SLC19A1 | SLC6A2 328/4885ADORA2A 964/4885DHFR 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.